Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

Key Inclusion Criteria: * Chronic genotype 1-4 HCV infection * For Cohorts 1-9, HCV RNA ≥ 100,000 IU/mL at screening (no HCV RNA restriction for Cohort 10) * Screening laboratory values within defined thresholds * Use of two effective contraception methods if female of childbearing potential or sexually active male Key Exclusion Criteria: * Pregnant or nursing female or male with pregnant female partner * Presence of cirrhosis * Prior exposure to approved or experimental HCV Protease Inhibitors * Co-infection with HIV or hepatitis B virus (HBV) * Current or prior history of clinical hepatic decompensation * Chronic use of systemic immunosuppressive agents * History of clinically significant illness or any other medical disorder that may interfere with participant's treatment, assessment or compliance with the protocol Note: Other protocol defined Inclusion/Exclusion criteria may apply.